Immunotherapy Collection | Blood Cancer Discovery | American Association for Cancer Research
The collection showcases recent advances published in Blood Cancer Discovery on immunotherapy. This research holds promise to enhance clinical benefit
Related Articles
Unraveling the Therapeutic Benefit of Sequenced Chemo-immunotherapy
Summary. Combination immune-checkpoint inhibition with chemotherapy is a clinical standard, yet concurrent administration may limit the full benefit of immunotherapy by blunting the proliferation and…
A Novel Approach for Conducting a Catchment Area Analysis of Breast Cancer by Age and Stage for a Community Cancer Center
AbstractBackground:. The U.S. Preventive Services Task Force recently issued an updated draft recommendation statement to initiate breast cancer screening at age 40, reflecting well-documented disparities…
Convergence Science | Cancer Research | American Association for Cancer Research
Convergence Science | Cancer Research | American Association for Cancer Research .aacrcontent { display: flex; flex-direction: row; justify-content: space-between; align-items: stretch; } .intro { margin-top:…
Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Clinical Response in NRASG12C Cancers
Sotorasib and other selected KRASG12C inhibitors leverage differential dependence on switch-II pocket binding at amino acid position 95 to target all RASG12C isoforms, which has…
Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B Cell Lymphoma
Abstract. Polatuzumab Vedotin (Pola-V) is an antibody-drug conjugate directed to the CD79B subunit of the B cell receptor (BCR). When combined with conventional immunochemotherapy, Pola-V…
Effect of Clonal Hematopoiesis Mutations and Canakinumab Treatment on Incidence of Solid Tumors in the CANTOS Randomized Clinical Trial
Abstract. Clonal hematopoiesis (CH) is more common in older persons and has been associated with an increased risk of hematological cancers and cardiovascular diseases. The…
Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B Cell Lymphoma
Abstract. Polatuzumab Vedotin (Pola-V) is an antibody-drug conjugate directed to the CD79B subunit of the B cell receptor (BCR). When combined with conventional immunochemotherapy, Pola-V…
Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases
A multi-cohort, pan-cancer analysis uncovered racial disparities in cancer genomes between Asian and White populations and elucidated pairwise relationships of driver alterations, providing valuable resources…
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer
Quantification of the precision oncology landscape and clinical actionability in patients with cancer shows an increase in the fraction of genomic biomarkers of response to…
RAS G12C Inhibitors: Three Birds with One Stone
Summary:. In this issue, Rubinson, Tanaka, and colleagues demonstrate that differences among G12C inhibitors rely on their ability to covalently bind not only G12C mutant…